美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

CoLucid Pharmaceuticals, Inc.

46.53

0.0000

成交量：- -

成交額：- -

市值：8.97億

市盈率：-13.52

高：46.53

開：46.53

低：46.53

收：46.53

52周最高：46.65

52周最低：5.26

股本：1,928.43萬

流通股本：479.00萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-3.4400

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

CoLucid Pharmaceuticals, Inc.

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.colucid.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Colucid製藥公司於2005年8月31日在美國特拉華州註冊成立，2005年12月16日，公司收購了或獨家授權了Eli Lilly的對特定臨床和臨床前項目的商業開發權以及知識產權。這是正在開發的創新和專有小分子的急性治療偏頭痛三期臨床階段的生物製藥公司。該公司的候選產品使用的行動在過去二十年的第一個新的機制，它相信可以解決偏頭痛患者，包括那些與心血管危險因素或穩定的心血管疾病和那些誰是不滿現有療法的未滿足的需求。Lasmiditan，其先導候選產品，是一種口服的片劑用於治療急性偏頭痛成人不具有與最常用的治療相關的臨床局限性。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CLCD/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLCD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLCD\",,,,,undefined,":{"symbol":"CLCD","market":"US","secType":"STK","nameCN":"CoLucid Pharmaceuticals, Inc.","latestPrice":46.525,"timestamp":1488315600000,"preClose":46.525,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":4790000,"shares":19284290,"eps":-3.44,"marketStatus":"未開盤","change":0,"latestTime":"02-28 16:00:00 EST","open":46.525,"high":46.525,"low":46.525,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.44,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771923600000},"marketStatusCode":0,"adr":0,"listingDate":1430884800000,"exchange":"NASDAQ","adjPreClose":46.525,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLCD\",,,,,undefined,":{"symbol":"CLCD","floatShares":4790000,"roa":"--","roe":"--","lyrEps":0,"shares":19284290,"dividePrice":0,"high":46.525,"amplitude":0,"preClose":46.525,"low":46.525,"week52Low":5.2558,"pbRate":"--","week52High":46.65,"institutionHeld":0,"latestPrice":46.525,"eps":-3.44,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.44,"open":46.525,"prevYearClose":46.525},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLCD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2016-08-10","symbol":"CLCD","fiscalQuarterEnding":null,"expectedEps":-0.83,"name":null,"time":"","type":"earning","dateTimestamp":1470801600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2016-05-11","symbol":"CLCD","fiscalQuarterEnding":null,"expectedEps":-0.73,"name":null,"time":"","type":"earning","dateTimestamp":1462939200000,"reportTimeType":"","actualEps":-0.85},{"market":"US","date":"2016-03-02","symbol":"CLCD","fiscalQuarterEnding":null,"expectedEps":-0.66,"name":null,"time":"","type":"earning","dateTimestamp":1456894800000,"reportTimeType":"","actualEps":-0.74},{"market":"US","date":"2015-11-10","symbol":"CLCD","fiscalQuarterEnding":null,"expectedEps":-0.71,"name":null,"time":"","type":"earning","dateTimestamp":1447131600000,"reportTimeType":"","actualEps":-0.59},{"market":"US","date":"2015-08-12","symbol":"CLCD","fiscalQuarterEnding":null,"expectedEps":-0.4,"name":null,"time":"","type":"earning","dateTimestamp":1439352000000,"reportTimeType":"","actualEps":-1.17}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLCD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLCD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.colucid.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Colucid製藥公司於2005年8月31日在美國特拉華州註冊成立，2005年12月16日，公司收購了或獨家授權了Eli Lilly的對特定臨床和臨床前項目的商業開發權以及知識產權。這是正在開發的創新和專有小分子的急性治療偏頭痛三期臨床階段的生物製藥公司。該公司的候選產品使用的行動在過去二十年的第一個新的機制，它相信可以解決偏頭痛患者，包括那些與心血管危險因素或穩定的心血管疾病和那些誰是不滿現有療法的未滿足的需求。Lasmiditan，其先導候選產品，是一種口服的片劑用於治療急性偏頭痛成人不具有與最常用的治療相關的臨床局限性。","exchange":"NASDAQ","name":"CoLucid Pharmaceuticals, Inc.","nameEN":"CoLucid Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"CLCD\",market:\"US\",,,undefined,":null}}